500 Participants Needed

Smartphone Flicker Fusion Test for Vision Impairment

JK
JF
Overseen ByJan Full, BSN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Randy Kardon
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment eyeFusion for vision impairment?

The research highlights the use of critical flicker fusion frequency (CFF) as a tool to assess visual function, which is relevant to the smartphone-based flicker fusion test in the trial. CFF has been used to evaluate visual function in conditions like cataracts and age-related macular degeneration, suggesting its potential utility in assessing vision impairment.12345

How is the eyeFusion treatment different from other treatments for vision impairment?

The eyeFusion treatment is unique because it uses a smartphone-based flicker fusion test to assess vision impairment, which is a novel approach compared to traditional methods. This method leverages technology to potentially offer a more accessible and convenient way to monitor visual function.16789

What is the purpose of this trial?

The purpose of this project is to validate a quick, easy-to-use and administer smartphone flicker fusion test. The app (called eyeFusion) can potentially be used to easily and quickly collect critical flicker fusion measurements on patients admitted with optic disorders as part of the clinical care process.

Research Team

RK

Randy Kardon, MD, PhD

Principal Investigator

University of Iowa

Eligibility Criteria

This trial is for people aged 18-80 with or without optic disorders. Healthy individuals with no known eye issues can join as controls, while those experiencing a blind spot (scotoma) are the patient group. Those with other ocular conditions cannot participate.

Inclusion Criteria

I have a blind spot in my vision.
I have no known eye disorders.

Exclusion Criteria

I have another eye condition.
I have a blind spot or another eye condition.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Testing

Participants use the eyeFusion app to measure flicker fusion thresholds

Less than 2 minutes per session
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after testing

1 week

Treatment Details

Interventions

  • eyeFusion
Trial Overview The study is testing an app called eyeFusion on smartphones to see if it's effective in measuring flicker fusion (the speed at which a flickering light appears steady) in patients with optic disorders.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: eyeFusion PatientsExperimental Treatment1 Intervention
Scotoma subjects aged 18-80.
Group II: eyeFusion Control SubjectsActive Control1 Intervention
Healthy normal controls with no known eye disorders age 18-80.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Randy Kardon

Lead Sponsor

Trials
4
Recruited
1,100+

Findings from Research

Critical flicker-fusion frequency (CFF) was found to be significantly lower in patients with both non-exsudative and exsudative age-related macular degeneration (AMD), indicating a decline in visual processing speed associated with the disease.
CFF measurements could not differentiate between AMD patients and healthy individuals with similar visual acuity, suggesting that CFF is not a reliable diagnostic tool for AMD.
Critical flicker-fusion frequency in age-related macular degeneration.Maier, M., Groneberg, T., Specht, H., et al.[2021]
Critical flicker/fusion (CFF) thresholds can effectively differentiate between patients with macular disease and those with media opacity, making it a useful potential vision test (PVT) for assessing retinal health.
In a study of 72 patients, CFF values were significantly lower in those with macular disease compared to those with media opacity or pseudophakia, indicating that CFF testing is not affected by media opacity but is sensitive to retinal disease.
Development of a critical flicker/fusion frequency test for potential vision testing in media opacities.Vianya-Estopà, M., Douthwaite, WA., Pesudovs, K., et al.[2004]
The critical flicker fusion frequency (CFF) test is a sensitive tool for detecting visual function changes in cataract patients, effectively distinguishing between simple cataracts and those with additional fundus diseases.
CFF can predict postoperative visual acuity more accurately than traditional tests, especially in cases with dense cataracts, making it a valuable tool for assessing visual prognosis in these patients.
The theory of critical flicker fusion frequency and its application in cataracts.Xu, G., Fu, J., Qi, H., et al.[2023]

References

Critical flicker-fusion frequency in age-related macular degeneration. [2021]
Development of a critical flicker/fusion frequency test for potential vision testing in media opacities. [2004]
The theory of critical flicker fusion frequency and its application in cataracts. [2023]
Mobility improvement of patients with peripheral visual field losses using novel see-through digital spectacles. [2020]
Smartphone use in ophthalmology: What is their place in clinical practice? [2021]
Refinement and preliminary evaluation of two tablet-based tests of real-world visual function. [2021]
Psychophysics, reliability, and norm values for temporal contrast sensitivity implemented on the two alternative forced choice C-Quant device. [2019]
[Critical (foveal) flicker fusion frequency (CFF) is helpful in differential diagnosis of organic lesions from orthoptic amblyopias]. [2009]
Development and validation of a new glaucoma screening test using temporally modulated flicker. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security